Literature DB >> 10501170

Newcastle disease virus strain I2--a prospective thermostable vaccine for use in developing countries.

Z Bensink1, P Spradbrow.   

Abstract

Forty-five avirulent Australian strains of Newcastle disease virus had been examined for antigenicity in chickens and 18 of these were tested for thermostability. Strain I2, chosen for a combination of antigenicity and thermostability, was artificially selected for enhanced thermostability. Master seed material was then prepared in minimal disease eggs, and vaccine by a further two passages in conventional eggs. Strain I2 virus at seed and vaccine level induced adequate levels of antibody in chickens vaccinated by eye drop and usually in their contacts. The serological response to oral vaccination was less certain. Antibody titres indicative of substantial protection against virulent challenge were maintained in a simulated village flock for 38 weeks by vaccination of the foundation flock on two occasions, with subsequent vaccination confined to clutches of chicks as they were produced. Strain I2 virus survived for at least 12 weeks when stored at 22 degrees C in 1% gelatin. Strain I2 is suitable for local production of thermostable vaccine in regional laboratories in developing countries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501170     DOI: 10.1016/s0378-1135(99)00069-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  30 in total

1.  Putative protective antibody response following oral vaccination of multi-age free ranging helmeted guinea fowls (Numida meleagris) with Newcastle disease virus strain I-2 coated on oiled rice.

Authors:  Philemon N Wambura; S Kataga
Journal:  Trop Anim Health Prod       Date:  2010-09-29       Impact factor: 1.559

2.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

3.  Molecular Characterization of Thermostable Newcastle disease virus Isolated from Pigeon.

Authors:  A Uthrakumar; K Vijayarani; K Kumanan; V Thiagarajan
Journal:  Indian J Virol       Date:  2013-01-29

4.  Deduced amino acid sequences surrounding the fusion glycoprotein cleavage site and of the carboxyl-terminus of haemagglutinin-neuraminidase protein of the avirulent thermostable vaccine strain I-2 of Newcastle disease virus.

Authors:  P N Wambura; J Meers; J A Kattenbelt; A R Gould; P B Spradbrow
Journal:  Vet Res Commun       Date:  2006-12-29       Impact factor: 2.459

5.  Formulation of novel nano-encapsulated Newcastle disease vaccine tablets for vaccination of village chickens.

Authors:  Philemon N Wambura
Journal:  Trop Anim Health Prod       Date:  2010-08-04       Impact factor: 1.559

6.  Development of a cell culture method for quantal assay of strain I-2 of Newcastle disease virus.

Authors:  P Wambura; J Meers; P Spradbrow
Journal:  Vet Res Commun       Date:  2006-08       Impact factor: 2.459

7.  Protective antibody response produced by the chickens vaccinated with green coloured thermostable Newcastle disease virus.

Authors:  P N Wambura
Journal:  Trop Anim Health Prod       Date:  2008-06-20       Impact factor: 1.559

8.  An assessment of chicken husbandry including Newcastle disease control in rural areas of Chibuto, Mozambique.

Authors:  Jennifer L Harrison; Robyn G Alders
Journal:  Trop Anim Health Prod       Date:  2009-11-10       Impact factor: 1.559

9.  Protective antibody response following oral vaccination of feral pigeons (Columba livia) with Newcastle disease vaccine (strain I-2) coated on oiled rice.

Authors:  P N Wambura; C Wilson
Journal:  Vet Res Commun       Date:  2009-12       Impact factor: 2.459

10.  Pathotyping of a Newcastle disease virus isolated from peacock (Pavo cristatus).

Authors:  K Vijayarani; S Muthusamy; K G Tirumurugaan; S M Sakthivelan; K Kumanan
Journal:  Trop Anim Health Prod       Date:  2009-09-08       Impact factor: 1.559

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.